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Askin tumors are highly malignant thoracopulmonarytumors mainly occurring in children and adolescents.An aggressive multimodal approach (chemotherapy,surgery and radiotherapy) is the common treatment.1,2
Takanami and associates3 recently reported on 2 long-surviving
patients with Askin tumors first treated by surgery. They suggested
that the best treatment schedule was surgery followed by chemo-
therapy, with or without radiotherapy, highlighting the issue of the
best timing of chemotherapy in this disease. In our opinion many
reasons justify the use of chemotherapy in a preoperative setting,
including a safer and simpler surgery and the possibility to use
information about tumor chemosensitivity to plan postoperative
chemotherapy and radiotherapy. On this basis we treated Askin
tumor with a multimodal approach that included induction chemo-
therapy. Here we present our favorable results with this schedule
of treatments and briefly review salient literature data.
Clinical Summary
Table 1 summarizes the clinical characteristics and outcomes of 5
patients with Askin tumor treated from 1998 to 2002. Patient 1 had
been treated surgically elsewhere for “undifferentiated lung can-
cer” of the upper left lobe and came to us 3 months later with a
supraclavicular recurrence. We gave him a cisplatin-based regimen
followed by radiotherapy and obtained a complete response. A
year later there was a localized chest wall recurrence, so we
completed the left upper lobectomy with chest wall resection.
Pathologic examination of the specimen demonstrated Askin tu-
mor, and appropriate adjuvant chemotherapy was also given. A
cycle of concomitant radiotherapy and chemotherapy was given a
year later to treat a further local recurrence. At present this patient
is alive with disease.
Of the other 4 patients, 2 had their diagnoses made at our center
after percutaneous biopsy before treatment, and the other 2 had
their diagnoses made elsewhere by surgical biopsy. All of them
received preoperative and postoperative chemotherapy alternating
two drug regimens (ifosfamide, vincristine, and doxorubicin and
ifosfamide and etoposide) for four to six cycles, with additional
high-dose ifosfamide, carboplatin, and etoposide in 2 cases (1
before and 1 after the operation). Radical and safe surgical exci-
sion was achieved in all these cases, with chest wall resection of
one to five ribs and en bloc lung resection when infiltration was
present (2 cases). Postoperative radiotherapy (60 Gy) was given
in all but 1 case. The type of adjuvant treatment was chosen on the
basis of clinical and pathologic responses to chemotherapy. In
particular, high-dose treatment was discussed and offered to those
patients with worse prognoses, such as presence of a high percent-
age of live cells at the postinduction pathologic examination.
Radiotherapy was avoided in 1 patient with good prognostic fac-
tors. No major toxicity related to chemotherapy was observed,
neither were any postoperative complications seen.
Figures 1 and 2 provide a vivid example of the advantages of
induction chemotherapy. Patient 4 initially had unresectable, bulky
disease, but the lesion could be removed completely after induc-
tion chemotherapy.
Discussion
Compared with the postoperative approach, preoperative chemo-
therapy favors a more conservative surgical approach and thus
better postoperative function, reduces the risk of intraoperative
tumor rupture and tumor cell dissemination, increases the proba-
bility of complete surgical resection, favors the sterilization of any
occult distant spread, and allows pathologic and clinical evaluation
of the response, favoring the choice of the best postoperative
regimen of chemotherapy and radiotherapy.
In 53 patients with nonmetastatic chest wall primary cancers
included in the First Intergroup Ewing Sarcoma Study,2 the recur-
rence rate was lower with induction chemotherapy than with
chemotherapy given subsequently. In a retrospective study pub-
lished in 1996, Sawin and associates3 found that preoperative
chemotherapy prolonged survival relative to later chemotherapy
and was associated with a significant reduction in tumor size that
facilitated resection. In 2000 Christiansen and colleagues4 reported
on 8 patients with Askin tumor and concluded that the best
treatment should include preoperative and postoperative chemo-
therapy, radical surgical resection, and irradiation, generally post-
operative but preoperative in selected cases. In their series the 4
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patients with complete resection were alive at a median follow-up
of 30 months, whereas the 4 with extended disease and marginal
surgery died, suggesting that complete surgical resection is an
important prognostic factor.
Our own experience is fully consonant with these findings.
Preoperative chemotherapy was always feasible. In the 4 cases we
saw at first diagnosis, it provided high antitumor activity and no
major toxicity, allowing complete and safe surgical resection.
More appropriate adjuvant treatment was chosen on the basis of
pathologic and clinical responses to induction treatment. The ex-
ample of patient 4 (Figures 1 and 2), who initially had a nonre-
sectable mass but after induction was able to undergo complete
surgical resection, is particularly gratifying. We therefore suggest
that aggressive treatment with preoperative chemotherapy, radical
surgical resection, postoperative chemotherapy, and irradiation is
the best approach to Askin tumor.
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Figure 1. Chest computed tomographic scans of patient 4 before (A) and after (B) chemotherapy, showing
impressive response of bulky Askin tumor.
Figure 2. Surgical specimen of Askin tumor from patient 4, in-
cluding posterolateral sections of three ribs, lesion, and wedge
resection of lower lobe.
TABLE 1. Clinical characteristics of five patients with Askin tumor
Patient
Age (y),
sex Surgery Therapy Status DFI (mo)
Survival
(mo)
1 36, M LUL  CW (III-V ribs) S-CT-RT-CT REC 3 53
2 22, M CW (VII rib) CT-S-HDCT-RT Died 13 14
3 14, M CW (VI-X ribs) CT-S-CT NED 30 30
4 14, M WR LLL  CW (V-VII ribs) CT-S-CT-RT NED 20 20
5 28, F CW (II-IV ribs) CT-S-RT NED 41 41
DFI, Disease-free interval; M, male; F, female; S, surgery; CT, chemotherapy; RT, radiotherapy; REC, alive with recurrence; NED, no evidence of disease;
WR LLL, wedge resection left lower lobe; LUL, left upper lobectomy; CW, chest wall resection; HD, high dose.
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